These results highlight the power of predictive biomarkers to guide precision medicine and pave the way for biomarker-driven clinical trials in advanced prostate cancer.
Huge thanks to everyone involved!
🧵4/4

🔵 MCL1 + AKT inhibition synergistically induces apoptosis in PTEN-loss/PI3K-activated models → patients with these aberrations may benefit most.
🔵 CDK9 inhibition (fadraciclib) + AKT blockade mirrors MCL1i+AKTi combination effects, offering another therapeutic strategy.
🧵3/4

We investigated the role of MCL1, a key anti-apoptotic protein, in lethal prostate cancer.

Key findings:
🔵 MCL1 copy number gain occurs in a subset of patients → more aggressive disease & poorer outcomes.
🔵 MCL1-targeted monotherapy may benefit these patients.
🧵2/4

🚨 Delighted to share our latest paper, from
@asharpmedonc.bsky.social team in collaboration with Johann de Bono’s team at @icr.ac.uk and international colleagues, published in Nature Communications @natureportfolio.nature.com
Read here: bit.ly/477pYt7
🧵1/4

Thank you, Ana! Enjoy London!

Teamwork makes the dream works! Thank you, PCUK, for your support! @prostatecanceruk.bsky.social
@prostateukprofs.bsky.social

Could targeting MCL1 be a new treatment approach for hormone therapy-resistant #ProstateCancer?

A study in @natcomms.nature.com by @juanjimenezvacas.bsky.social, @asharpmedonc.bsky.social and the @icr.ac.uk team explores precision therapy strategies.

Grab a ☕ and read: doi.org/10.1038/s414...